Simvastatin efficiently lowers small LDL-IgG immune complex levels: A therapeutic quality beyond the lipid-lowering effect

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Hörl, Gerd ^a   Froehlich, Harald ^a   Ferstl, Ulrika ^a   Ledinski, Gerhard ^a   Binder, Josepha ^a   Cvirn, Gerhard ^a   Stojakovic, Tatjana ^a   Trauner, Michael ^b   Koidl, Christoph ^a   Tafeit, Erwin ^a   Amrein, Karin ^a   Scharnagl, Hubert ^a   Jürgens, Günther ^a   Hallström, Seth ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SIMVASTATIN; ANTIGEN ANTIBODY COMPLEX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AEROBIC METABOLISM; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; ELECTROPHORESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARTICLE SIZE; SIZE EXCLUSION CHROMATOGRAPHY; ULTRACENTRIFUGATION; BLOOD; CORONARY RESTENOSIS; IMMUNOLOGY; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-ANTIBODY COMPLEX; APOLIPOPROTEINS B; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULIN G; MALE; MALONDIALDEHYDE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; SIMVASTATIN;

EID: 84959020449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148210     Document Type: Article

References (76)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989; 320(14):915-24. PMID: 2648148
2. Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014; 129(15):1551-9. doi: 10.1161/CIRCULATIONAHA.113.005015 PMID: 24481950
3. Orekhov AN, Bobryshev YV, Sobenin IA, Melnichenko AA, Chistiakov DA. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. International journal of molecular sciences. 2014; 15(7):12807-41. doi: 10.3390/ijms150712807 PMID: 25050779
4. Soto Y, Conde H, Aroche R, Brito V, Luaces P, Nasiff A, et al. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease. Hum Antibodies. 2009; 18(3):109-17. doi: 10.3233/HAB-2009-0202 PMID: 19729805
5. Matsuura E, Kobayashi K, Lopez LR. Atherosclerosis in autoimmune diseases. Curr Rheumatol Rep. 2009; 11(1):61-9. PMID: 19171113
6. van Leeuwen M, Damoiseaux J, Duijvestijn A, Tervaert JW. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev. 2009; 9(1):53-7. doi: 10.1016/j. autrev.2009.03.001 PMID: 19285155
7. Chyu KY, Shah PK. Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases. Therapeutic advances in vaccines. 2014; 2(2):56-66. doi: 10.1177/2051013613514327 PMID: 24757525
8. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005; 112(21):3337-47. PMID: 16301360
9. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosis. Autoimmun Rev. 2002; 1(6):348-53. PMID: 12848990
10. Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010; 134(1):55-65. doi: 10.1016/j.clim.2009.04.001 PMID: 19427818
11. Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, et al. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood. 2012; 120(22):4421-31. doi: 10.1182/blood-2011-12-401133 PMID: 22955924
12. Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol. 2010; 134(1):47-54. doi: 10. 1016/j.clim.2009.08.013 PMID: 19748321
13. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation. 2004; 110(17):2552-8. PMID: 15505108
14. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis. 2006; 188(1):160-6. PMID: 16307748
15. Wu R, Huang YH, Elinder LS, Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol. 1998; 18(4):626-30. PMID: 9555869
16. Atchley DH, Lopes-Virella MF, Zheng D, Kenny D, Virella G. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia. 2002; 45(11):1562-71. PMID: 12436340
17. Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, et al. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007; 190(2):359-69. PMID: 16530770
18. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999; 90(2):165-72. PMID: 10080827
19. Mironova MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000; 49(6):1033-41. PMID: 10866057
20. Lopes-Virella MF, Mironova M, Stephan E, Durazo-Arvizu R, Virella G. Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care. 2004; 27(4):908-13. PMID: 15047647
21. Timar O, Szekanecz Z, Kerekes G, Vegh J, Olah AV, Nagy G, et al. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis - a prospective case-series study. Arthritis research & therapy. 2013; 15(5):R105.
22. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004; 110 (11):1406-12. PMID: 15353498
23. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009; 53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041 PMID: 19497447
24. Tertov VV, Sobenin IA, Orekhov AN, Jaakkola O, Solakivi T, Nikkari T. Characteristics of low density lipoprotein isolated from circulating immune complexes. Atherosclerosis. 1996; 122(2):191-9. PMID: 8769682
25. Stojakovic T, de Campo A, Scharnagl H, Sourij H, Schmolzer I, Wascher TC, et al. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest. 2010; 40(3):187-94. doi: 10.1111/j.1365-2362.2009.02249.x PMID: 20067513
26. Davies IG, Graham JM, Griffin BA. Rapid separation of LDL subclasses by iodixanol gradient ultracentrifugation. Clin Chem. 2003; 49(11):1865-72. PMID: 14578318
27. Yee MS, Pavitt DV, Tan T, Venkatesan S, Godsland IF, Richmond W, et al. Lipoprotein separation in a novel iodixanol density gradient, for composition, density, and phenotype analysis. J Lipid Res. 2008; 49(6):1364-71. doi: 10.1194/jlr.D700044-JLR200 PMID: 18337616
28. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering. Biochimica et biophysica acta. 1990; 1037(1):48-57. PMID: 2294970
29. Hammer A, Kager G, Dohr G, Rabl H, Ghassempur I, Jurgens G. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler Thromb Vasc Biol. 1995; 15(5):704-13. PMID: 7749884
30. Pilz J, Meineke I, Gleiter CH. Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative. J Chromatogr B Biomed Sci Appl. 2000; 742(2):315-25. PMID: 10901136
31. Singh Y, Lakshmy R, Gupta R, Kranthi V. A rapid 3% polyacrylamide slab gel electrophoresis method for high through put screening of LDL phenotype. Lipids in health and disease. 2008; 7:47. doi: 10. 1186/1476-511X-7-47 PMID: 19036141
32. Klein RL, Carter RE, Jenkins AJ, Lyons TJ, Baker NL, Gilbert GE, et al. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011; 25(2):73-82. doi: 10.1016/j.jdiacomp.2010.03.001 PMID: 20605479
33. Virella G, Colglazier J, Chassereau C, Hunt KJ, Baker NL, Lopes-Virella MF. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74. doi: 10.1080/15321819.2012.683500 PMID: 23323982
34. Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allergy Immunol. 2009; 37(1):4-11. doi: 10.1007/s12016-008-8095-9 PMID: 18987785
35. Carroll RM, Rudel LL. Lipoprotein separation and low density lipoprotein molecular weight determination using high performance gel-filtration chromatography. J Lipid Res. 1983; 24(2):200-7. PMID: 6833895
36. Klimov AN, Denisenko AD, Vinogradov AG, Nagornev VA, Pivovarova YI, Sitnikova OD, et al. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis. 1988; 74(1-2):41-6. PMID: 3214480
37. Chapman MJ, Laplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988; 29(4):442-58. PMID: 3392462
38. Schumaker VN, Phillips ML, Chatterton JE. Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. Advances in protein chemistry. 1994; 45:205-48. PMID: 8154370
39. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 1998; 19 Suppl A:A24-30. PMID: 9519339
40. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004; 109(23 Suppl 1):III2-7. PMID: 15198959
41. Chait A, Wight TN. Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr Opin Lipidol. 2000; 11(5):457-63. PMID: 11048888
42. Younis NN, Soran H, Pemberton P, Charlton-Menys V, El-Seweidy MM, Durrington PN. Small dense LDL is more susceptible to glycation than more buoyant LDL in type 2 diabetes. Clin Sci (Lond). 2012.
43. Tribble DL, Krauss RM, Lansberg MG, Thiel PM, van den Berg JJ. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. J Lipid Res. 1995; 36(4):662-71. PMID: 7616114
44. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull. 2003; 26(1):1-9. PMID: 12520163
45. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000; 20(10):2243-7. PMID: 11031210
46. Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, et al. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013; 231(2):315-22. doi: 10.1016/j.atherosclerosis.2013.09.027 PMID: 24267245
47. Sobenin IA, Orekhova VA, Melnichenko Acapital A C, Bobryshev YV, Orekhov AN. Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. International journal of cardiology. 2013; 166 (3):747-8. doi: 10.1016/j.ijcard.2012.09.175 PMID: 23073276
48. Sparrow CP, Parthasarathy S, Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res. 1988; 29(6):745-53. PMID: 3139813
49. Estruch M, Rajamaki K, Sanchez-Quesada JL, Kovanen PT, Oorni K, Benitez S, et al. Electronegative LDL induces priming and inflammasome activation leading to IL-1beta release in human monocytes and macrophages. Biochimica et biophysica acta. 2015; 1851(11):1442-9. doi: 10.1016/j.bbalip.2015. 08.009 PMID: 26327597
50. Tertov VV, Bittolo-Bon G, Sobenin IA, Cazzolato G, Orekhov AN, Avogaro P. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol. 1995; 62(3):166-72. PMID: 8612720
51. Nilsson J, Bjorkbacka H, Fredrikson GN. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr Opin Lipidol. 2012; 23(5):422-8. doi: 10.1097/MOL. 0b013e328356ec7c PMID: 22814703
52. Gutierrez MM, Tsai SW, Phillips ML, Curtiss LK, Milne RW, Schumaker VN. Studying low-density lipoprotein-monoclonal antibody complexes using dynamic laser light scattering and analytical ultracentrifugation. Biochemistry. 1999; 38(4):1284-92. PMID: 9930989
53. Nordestgaard BG. The vascular endothelial barrier - selective retention of lipoproteins. Curr Opin Lipidol. 1996; 7(5):269-73. PMID: 8937515
54. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007; 28(2):88-98. PMID: 17197237
55. Goncalves I, Cherfan P, Soderberg I, Nordin Fredrikson G, Jonasson L. Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers. Autoimmunity. 2009; 42(3):203-8. doi: 10.1080/08916930802668602 PMID: 19301201
56. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006; 47(9):1975-83. PMID: 16804192
57. Nilsson J, Bjorkbacka H, Fredrikson GN. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr Opin Lipidol. 2012; 23(5):422-8. doi: 10.1097/MOL. 0b013e328356ec7c PMID: 22814703
58. Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation. 2011; 123(10):1083-91. doi: 10.1161/CIRCULATIONAHA.110.973222 PMID: 21357823
59. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation. 2003; 108(17):2107-12. PMID: 14530200
60. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011; 52 (10):1829-36. doi: 10.1194/jlr.M015776 PMID: 21821825
61. Fagerberg B, Prahl Gullberg U, Alm R, Nilsson J, Fredrikson GN. Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-yearold women. PloS one. 2015; 10(3):e0120744. doi: 10.1371/journal.pone.0120744 PMID: 25768285
62. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2009; 120(5):417-26. doi: 10.1161/CIRCULATIONAHA.109.868158 PMID: 19620499
63. Kobayashi K, Tada K, Itabe H, Ueno T, Liu PH, Tsutsumi A, et al. Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus. 2007; 16(12):929-38. PMID: 18042586
64. Zhang X, Xie Y, Zhou H, Xu Y, Liu J, Xie H, et al. Involvement of TLR4 in oxidized LDL/beta2GPI/antibeta2GPI-induced transformation of macrophages to foam cells. J Atheroscler Thromb. 2014; 21 (11):1140-51. PMID: 24998486
65. Bassi N, Zampieri S, Ghirardello A, Tonon M, Zen M, Beggio S, et al. oxLDL/beta2GPI complex and anti-oxLDL/beta2GPI in SLE: prevalence and correlates. Autoimmunity. 2009; 42(4):289-91. PMID: 19811279
66. Nowak B, Szmyrka-Kaczmarek M, Durazinska A, Plaksej R, Borysewicz K, Korman L, et al. Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus. Adv Clin Exp Med. 2012; 21(3):331-5. PMID: 23214196
67. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nature immunology. 2011; 12 (3):204-12. doi: 10.1038/ni.2001 PMID: 21321594
68. Li S, Kievit P, Robertson AK, Kolumam G, Li X, von Wachenfeldt K, et al. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab. 2013; 2 (3):256-69. doi: 10.1016/j.molmet.2013.06.001 PMID: 24049738
69. Harmon EY, Fronhofer V 3rd, Keller RS, Feustel PJ, Zhu X, Xu H, et al. Anti-inflammatory immune skewing is atheroprotective: Apoe-/-FcgammaRIIb-/-mice develop fibrous carotid plaques. J Am Heart Assoc. 2014; 3(6):e001232. doi: 10.1161/JAHA.114.001232 PMID: 25516435
70. Zhu X, Ng HP, Lai YC, Craigo JK, Nagilla PS, Raghani P, et al. Scavenger receptor function of mouse Fcgamma receptor III contributes to progression of atherosclerosis in apolipoprotein E hyperlipidemic mice. J Immunol. 2014; 193(5):2483-95. doi: 10.4049/jimmunol.1303075 PMID: 25038257
71. Asciutto G, Dias NV, Edsfeldt A, Alm R, Fredrikson GN, Goncalves I, et al. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy. Atherosclerosis. 2015; 239(2):289-94. doi: 10.1016/j.atherosclerosis.2015.01. 023 PMID: 25682025
72. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nature reviews Immunology. 2014; 14(2):94-108. doi: 10.1038/nri3582 PMID: 24445665
73. Bancells C, Canals F, Benitez S, Colome N, Julve J, Ordonez-Llanos J, et al. Proteomic analysis of electronegative low-density lipoprotein. J Lipid Res. 2010; 51(12):3508-15. doi: 10.1194/jlr.M009258 PMID: 20699421
74. Polz E, Kostner GM. The binding of beta 2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Lett. 1979; 102(1):183-6. PMID: 222615
75. Agar C, de Groot PG, Levels JH, Marquart JA, Meijers JC. Beta2-glycoprotein I is incorrectly named apolipoprotein H. J Thromb Haemost. 2009; 7(1):235-6. doi: 10.1111/j.1538-7836.2008.03223.x PMID: 19017258
76. Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2010; 13(1):39-75. doi: 10.1089/ars.2009.2733 PMID: 19888833